PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellular therapies
(or Advanced Therapy Medicinal Products) from the Chief Pharmaceutical Inspectorate in Poland.

We can now seek permission to perform clinical trials at the site, including for diseases such as Type-
1 Diabetes (T1D) and Multiple Sclerosis with our lead asset PTG-007.

PolTREG has more than 17 years of experience treating patients. We have administered Treg cells to
more than 100 people over that period, either in hospital exemption procedures or in clinical trials.

Our state-of-the-art manufacturing facility contains:

  • 15 stand-alone production lines
  • annual capacity of 1500 therapies
  • 4000 sq. m of space